We have recently demonstrated that a marked decrease in OCT1 expression [2] and in the activity of this transporter due to the appearance of aberrant SLC22A1 variants [3] may affect the response of HCC and CGC to sorafenib. This evidence concerns the gene SLC22A1 and hepatocellular carcinoma.